Citius Pharmaceuticals and Citius Oncology entered a Third Amendment to a $3,800,111 promissory note dated August 16, 2024. The amendment aligns the note's maturity with a new senior debt facility, setting the maturity date to 91 days after the senior debt is fully satisfied. Previous maturity triggers related to capital raises, equity/debt issuances, or royalty-backed monetizations of LYMPHIR have been removed. A new voluntary conversion feature allows Citius Pharmaceuticals to convert the principal into Citius Oncology common stock at $0.90 per share, subject to approval. Cash prepayments of the note are prohibited prior to the new maturity date.